AstraZeneca

News

AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced breast cancer.

News

AstraZeneca stakes a claim to first-line treatment of HR+ breast cancer with its oral SERD, as Arvinas/Pfizer reveal their second-line data.

News

AstraZeneca has turned to another digital health partner to support its aspirations in chronic kidney disease (CKD).

News

AstraZeneca has its first regulatory approval for an inhaler product using a propellant with a massively reduced global warming potential.

News

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in early bladder cancer.

News

AstraZeneca and Daiichi Sankyo's Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time.